Turn Therapeutics Inc. TTRX

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived Nasdaq

requires, for purposes of this section, the terms "we," "us," or "the Company" or "Turn Therapeutics"

refer to Turn Therapeutics Inc.

non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Our lead program, GX-03, is being studied for moderate-to-severe

eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability

Last close 10.28 2026-10-23
Market cap $306.2M 2026-06-30 share count
52-week range 2.57 - 16.45

Valuation FY2025 figures against the last close

P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-0.12

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023
R&D $265.6K$246.0K—
SG&A $5.6M$1.6M—
Total operating expenses $5.9M$1.8M—
Operating income -$5.9M-$1.8M—
Net income -$3.2M-$1.8M—
EPS, basic -0.12-0.07—
EPS, diluted -0.12-0.07—
Shares, diluted (wtd. avg.) 27.7M26.6M—

Balance sheet

Fiscal year FY2025FY2024FY2023
Cash and equivalents $4.0M$498.3K$1.2M
Total current assets $5.2M$1.1M—
Other intangibles $922.2K$821.9K—
Total assets $12.2M$2.0M—
Total current liabilities $6.0M$707.9K—
Total liabilities $7.5M$2.2M—
Retained earnings -$22.4M-$19.2M—
Total equity $4.7M-$177.4K$85.8K

Cash flow

Fiscal year FY2025FY2024FY2023
Operating cash flow -$2.6M-$1.4M—
Stock-based compensation $419.2K$352.8K—
Investing cash flow -$153.0K-$99.5K—
Financing cash flow $6.9M$1.2M—

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-037505.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -4M -3M -2M -1M 0 Net income, FY2024: -1.8M Net income, FY2025: -3.2M FY2023 FY2024 FY2025
Fiscal year FY2023FY2024FY2025
Revenue — — —
Gross profit — — —
Net income — -$1.8M -$3.2M

Recent filings and events

  • Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Regulation FD disclosure Item 7.01
  • Regulation FD disclosure Item 7.01
  • Regulation FD disclosure Item 7.01
  • Regulation FD disclosure Item 7.01
  • Regulation FD disclosure Item 7.01
  • Regulation FD disclosure Item 7.01
  • Regulation FD disclosure Item 7.01
  • Results announced Item 2.02
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
LLY ELI LILLY & Co $1.20T 55.5x 44.7%
JNJ JOHNSON & JOHNSON $635.76B 23.9x 6.0%
ABBV AbbVie Inc. $504.76B 121.0x 8.6%
MRK Merck & Co., Inc. $358.41B 20.0x 1.3%
ABT ABBOTT LABORATORIES $180.63B 27.9x 5.7%
PFE PFIZER INC $171.16B 22.1x -1.6%
VRTX VERTEX PHARMACEUTICALS INC / MA $132.80B 34.2x 8.9%
BMY BRISTOL MYERS SQUIBB CO $125.59B 17.8x -0.2%